Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gushen Antai Pill is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Beijing Boran Pharmaceutical. It is primarily indicated for the prevention of miscarriage and the treatment of kidney deficiency-type fetal instability. In modern clinical practice, it is frequently utilized as an adjuvant therapy for women undergoing in vitro fertilization and embryo transfer (IVF-ET) or frozen embryo transfer (FET) to provide luteal phase support and improve ongoing pregnancy rates. The formulation consists of several herbal ingredients, including *Cuscuta chinensis*, *Dipsacus asper*, and *Rehmannia glutinosa*, which are thought to modulate the maternal-fetal interface, enhance endometrial receptivity, and regulate the immune-endocrine environment to support a healthy pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gushen Antai Pill.